Refractory Acute Myeloid Leukemia

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Stemline Therapeutics
1 program
1
TagraxofuspPhase 1/21 trial
Active Trials
NCT06561152Recruiting20Est. Oct 2028

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
Stemline TherapeuticsTagraxofusp

Clinical Trials (1)

Total enrollment: 20 patients across 1 trials

NCT06561152Stemline TherapeuticsTagraxofusp

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Start: Feb 2025Est. completion: Oct 202820 patients
Phase 1/2Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
8m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
8m ago

Office Administrator

SystImmune
8m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
19m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
22m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
22m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 20 patients
1 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)